Advice

following a resubmission:

argatroban (Exembol®) is accepted for use within NHS Scotland.

Indication under review: anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.

Argatroban produces anticoagulant effects in adults with heparin-induced thrombocytopenia type II.  However there is limited evidence that the anticoagulant effects are associated with a reduction in thrombosis and deaths due to thrombosis.
 

Download detailed advice137KB (PDF)

Download

Medicine details

Medicine name:
argatroban, 100mg/ml, concentrate for solution for infusion (Exembol®)
SMC ID:
812/12
Indication:
For anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.
Pharmaceutical company
Mitsubishi Pharma Europe Ltd
BNF chapter
Cardiovascular system
Submission type
Resubmission
Status
Accepted
Date advice published:
12 August 2013